Syncromune Presents Innovative Sync-T Immunotherapy Approach
In a single-arm Phase 1 study of 15 patients with metastatic prostate cancer, Syncromune’s SYNC-T Therapy SV-102 reported an...
eClinical Tech News
Promising New KRAS Inhibitor Trial Doses Its First Patient
Kestrel Therapeutics dosed the first patient in FALCON, its Phase 1, open-label dose-escalation and expansion study of KST-6051, an...
Noted Annovis Alzheimer’s Trial Results Published in Nature
A 12-week Phase 2/3 study in 351 patients with mild to moderate Alzheimer’s disease reported statistically significant, dose-dependent improvements...
FDA Fast Tracks Scancell’s Melanoma Drug After Phase 2 Data
Progression-free survival reached 77% at 20 months in the target HLA-selected population of Scancell’s Phase 2 SCOPE trial when...
Oral Semaglutide: A Breakthrough for Kids with Diabetes?
In the Phase 3a PIONEER TEENS study (n=132), oral semaglutide delivered a statistically significant 0.83% greater reduction in HbA1c...
Clinuvel Gets EMA Advice for Pivotal Phase III Vitiligo Study
EMA has issued final scientific advice clearing Clinuvel’s pivotal vitiligo trial to use a “totality of evidence” assessment anchored...
Nectero Reports 2-Year Safety and Efficacy Data for AAA
In a 46-patient first-in-human study of small- to medium-sized abdominal aortic aneurysms (AAA), Nectero’s investigational Nectero EAST System delivered...
Psyence Biomed Doses First Patient in Adjustment Disorder Trial
Psyence Biomedical has dosed the first patient in its Phase IIb study of NPX-5, a GMP-compliant, nature-derived psilocybin candidate,...
Epitopea Announces New Ovarian Cancer Clinical Trial Approval
Epitopea has secured UK MHRA and Regional Ethics Committee clearance to initiate OVACT, a first‑in‑human Phase 1/1b study of...
Maze Therapeutics Announces Sizable $150M Growth Offering
Maze Therapeutics priced a $150 million follow-on, selling 5.54 million shares at $23.50 and issuing 0.85 million pre-funded warrants...